Compare LOW & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOW | SNY |
|---|---|---|
| Founded | 1946 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.7B | 104.5B |
| IPO Year | 1994 | N/A |
| Metric | LOW | SNY |
|---|---|---|
| Price | $204.05 | $43.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 5 |
| Target Price | ★ $290.23 | $58.00 |
| AVG Volume (30 Days) | 2.1M | ★ 4.1M |
| Earning Date | 05-20-2026 | 04-23-2026 |
| Dividend Yield | 2.06% | ★ 3.47% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.90 | N/A |
| Revenue | ★ $86,286,000,000.00 | N/A |
| Revenue This Year | $9.16 | $3.49 |
| Revenue Next Year | $3.56 | $6.10 |
| P/E Ratio | $71.99 | ★ $6.14 |
| Revenue Growth | ★ 3.12 | N/A |
| 52 Week Low | $203.40 | $40.89 |
| 52 Week High | $293.06 | $52.68 |
| Indicator | LOW | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 38.28 | 53.79 |
| Support Level | N/A | $43.32 |
| Resistance Level | $228.06 | $45.18 |
| Average True Range (ATR) | 6.04 | 0.70 |
| MACD | -1.10 | 0.20 |
| Stochastic Oscillator | 3.57 | 76.40 |
Lowe's is the second-largest home improvement retailer globally, with 1,759 stores in the US, after the 2023 divestiture of its Canadian locations. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two-thirds of products sold. Lowe's primarily targets retail do-it-yourself (around 70% of sales) and do-it-for-me customers, but has expanded its professional business clients to 30% from less than 20% in the past seven years (set to expand further with the acquisition of FBM). We estimate Lowe's captures a high-single-digit share of the domestic home improvement market, based on US Census data and management's market size estimates.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.